BioCentury | Sep 19, 2020
Product Development

Sept. 18 ESMO roundup: data from Incyte, Autolus, Merck, Alkermes and Daiichi

...ORR was 71% with a CR of 64%. AUTO3 comprises two independent autologous CARs targeting CD19...
BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

...candidates —TAK-007, a Phase I/II-stage allogeneic CD19-targeted...
...NK cell therapy; TAK-940, a Phase I-stage CD19-targeted...
BioCentury | Sep 11, 2020
Translation in Brief

A compound to reduce adjuvanted vaccine side effects; an oncolytic virus to enable CAR T cells for solid tumors and more

...of Hope researchers described an oncolytic virus engineered to express a truncated CD19 that enabled anti-CD19...
...B cells 1 BC Staff University of Chicago City of Hope University of Luxembourg Icahn School of Medicine at Mount Sinai NIH CD19 DJ-1...
BioCentury | Aug 28, 2020
Distillery Therapeutics

CRISPR-based gene editing for Wiskott-Aldrich syndrome

...in B cells as well as WASp expression in 71.1% of CD45+ cells and 92.1% of CD19+...
BioCentury | Aug 28, 2020
Finance

Turning to solid tumors, cell therapy play Triumvira earns syndicate’s $55M vote of confidence

...CARs”).By late 2019, the company was preparing to start a Phase I/II trial of a TAC01-CD19...
BioCentury | Aug 20, 2020
Finance

Inhibrx, Harmony debut on NASDAQ as JW, Harbour line up on HKEX

...NDA for JW’s relmacabtagene autoleucel to treat third-line diffuse large B-cell lymphoma. The company thinks the anti-CD19...
BioCentury | Jul 28, 2020
Product Development

TCR2 gains on first signs of cell therapy efficacy in solid tumors

The earliest clinical efficacy data for TCR2’s mesothelin-targeted TRuC T cell therapy hint that the engineered TCR T cells may work in solid tumors, where CAR T cells have yet to shine. Shares of TCR...
BioCentury | Jul 25, 2020
Regulation

FDA makes Gilead’s Tecartus, for mantle cell lymphoma, third U.S.-approved CAR T

...A Gilead spokesperson told BioCentury the wholesale acquisition cost for a one-time infusion of the CD19-directed...
...Gilead’s Yescarta axicabtagene ciloleucel and Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN), which also target CD19...
...T cell therapy against CD19 (KTE-C19) (FKC-876) Gilead Sciences Inc. Kite Pharma Inc. bluebird bio Inc. Bristol Myers Squibb Co. CD19...
BioCentury | Jul 18, 2020
Translation in Brief

Fate licenses rejection-resistant T cell therapies; plus a marker for anti-PD-1 treatment responsiveness, a cell proliferation control switch and more

...selectively eliminating alloreactive T and NK cells. A Baylor team reported in Nature Biotechnology that anti-CD19...
...tumor eradication and survival benefit in xenograft mouse models of leukemia and neuroblastoma versus conventional CD19-targeting...
BioCentury | Jul 10, 2020
Product Development

Data Bytes: Cellectis remains active in allogeneic pipeline for multiple myeloma despite clinical hold

...comprises 12 candidates, seven of which target BCMA alone while an eighth targets BCMA plus CD19...
Items per page:
1 - 10 of 839